@article{0b8ce39304124596bdff117caa309dc0,
title = "Effect of empagliflozin on endothelial function in patients with type 2 diabetes and cardiovascular disease: Results from the multicenter, randomized, placebo- controlled, double-blind EMBLEM trial",
author = "Atsushi Tanaka and Michio Shimabukuro and Noritaka MacHii and Hiroki Teragawa and Yosuke Okada and Shima, {Kosuke R.} and Toshinari Takamura and Isao Taguchi and Itaru Hisauchi and Shigeru Toyoda and Yasushi Matsuzawa and Hirofumi Tomiyama and Minako Yamaoka-Tojo and Hisako Yoshida and Yasunori Sato and Yumi Ikehara and Shinichiro Ueda and Yukihito Higashi and Koichi Node",
note = "Funding Information: Acknowledgments. The authors thank the investigators, coordinators, and patients who participated in the trial. They also thank Takeshi Morimoto (Hyogo College of Medicine, Nishinomiya, Japan), Mitsuyoshi Urashima (Jikei University School of Medicine, Tokyo, Japan), and Takashi Nomiyama (Fukuoka University, Fukuoka, Japan), who served as members of the independent data and safety monitoring committee for the trial. Duality of Interest. This study was funded by Boehringer Ingelheim and Eli Lilly and Company. A.T. received modest honoraria from Astellas, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Kowa, Merck, Mitsubishi Tanabe, Novo Nordisk, Taisho Toyama, Takeda, and Teijin. M.S. received an honorarium and endowed chair from Boehringer Ingelheim. H.T. received lecture fees from Bayer, Boehringer Ingelheim, Daichi Sankyo, Kowa, Takeda, Mitsubishi Tanabe, and Sanwa Kagaku Kenkyusho. Y.O. received lecture fees from Astellas, AstraZeneca, Merck Sharp & Dohme (MSD), Ono, Mitsubishi Tanabe, Bayer, Novo Nordisk, Eli Lilly and Company, Boehringer Ingelheim, Daiichi Sankyo, Kissei, Novartis, Kowa, and Sanwa Kagaku Kenkyusho and research Figure 1—The mean (SD) RHI at baseline and at the 24-week follow-up. RHI values were increased ([RHI at 24 weeks] − [RHI at baseline] . 0) after 24 weeks of treatment in 21 patients (45%) in the empagliflozin group (red lines) and 24 patients (47%) in the placebo group (blue lines).",
year = "2019",
month = oct,
day = "1",
doi = "10.2337/dc19-1177",
language = "English",
volume = "42",
pages = "E159--E161",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "10",
}
